Payment overview · 2025
General Payments
$848.66
31 reported records · 12 companies
Healthcare provider profile · identity verified
Emad Nabil Gobran, MD
Allopathic & Osteopathic Physicians|Internal Medicine|Nephrology · TOMS RIVER, NJ · NPI 1376964023
Verified facts
What the public records show
CMS Open Payments records show Emad Nabil Gobran, MD received $848.66 in general payments during 2025 across 31 reported records.
Novo Nordisk Inc accounted for 27.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 16 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Kerendia, Ozempic.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $234.65 | 27.6% | 9 | 2025 |
| Davol Inc. | Unresolved — no canonical attribution shown | $150.00 | 17.7% | 1 | 2025 |
| OPKO Pharmaceuticals, LLC | Unresolved — no canonical attribution shown | $115.77 | 13.6% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $102.93 | 12.1% | 5 | 2025 |
| SCPHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $79.24 | 9.3% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $48.71 | 5.7% | 3 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $43.17 | 5.1% | 3 | 2025 |
| Chiesi USA, Inc. | Unresolved — no canonical attribution shown | $15.76 | 1.9% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $14.85 | 1.8% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $14.81 | 1.8% | 1 | 2025 |
| Calliditas Therapeutics US Inc. | Unresolved — no canonical attribution shown | $14.58 | 1.7% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $14.19 | 1.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $828.44 | 30 |
| Education | $20.22 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Phasix Mesh Normalized: phasix mesh |
Device | Davol Inc. | $150.00 | 1 | 2025 |
Source payment records
|
|||||
| RAYALDEE Normalized: rayaldee |
Drug | OPKO Pharmaceuticals, LLC | $115.77 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $102.93 | 5 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $85.38 | 5 | 2025 |
Source payment records
|
|||||
| FUROSCIX Normalized: furoscix |
Drug | SCPHARMACEUTICALS INC. | $79.24 | 3 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $43.17 | 3 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $35.36 | 3 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $30.10 | 2 | 2025 |
Source payment records
|
|||||
| UPLIZNA Normalized: uplizna |
Biological | Amgen Inc. | $18.61 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $16.53 | 1 | 2025 |
Source payment records
|
|||||
| CLEVIPREX Normalized: cleviprex |
Drug | Chiesi USA, Inc. | $15.76 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $14.85 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $14.85 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $14.81 | 1 | 2025 |
Source payment records
|
|||||
| TARPEYO Normalized: tarpeyo |
Drug | Calliditas Therapeutics US Inc. | $14.58 | 1 | 2025 |
Source payment records
|
|||||
| JYNARQUE Normalized: jynarque |
Drug | Otsuka America Pharmaceutical, Inc. | $14.19 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 33 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
33 | 12 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 279 | 93 |
| Levothyroxine Sodium | Levothyroxine Sodium | 216 | 56 |
| Eliquis | Apixaban | 199 | 40 |
| Amlodipine Besylate | Amlodipine Besylate | 178 | 59 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 156 | 58 |
| Metoprolol Succinate | Metoprolol Succinate | 155 | 65 |
| Pantoprazole Sodium | Pantoprazole Sodium | 148 | 47 |
| Nystatin | Nystatin | 142 | 21 |
| Furosemide | Furosemide | 128 | 55 |
| Metformin Hcl | Metformin Hcl | 128 | 45 |
| Tamsulosin Hcl | Tamsulosin Hcl | 126 | 53 |
| Metoprolol Tartrate | Metoprolol Tartrate | 115 | 33 |
| Losartan Potassium | Losartan Potassium | 109 | 45 |
| Lisinopril | Lisinopril | 105 | 49 |
| Clopidogrel | Clopidogrel Bisulfate | 91 | 26 |
| Gabapentin | Gabapentin | 91 | 24 |
| Potassium Chloride | Potassium Chloride | 90 | 30 |
| Silver Sulfadiazine | Silver Sulfadiazine | 73 | suppressed |
| Carvedilol | Carvedilol | 70 | 22 |
| Simvastatin | Simvastatin | 58 | 16 |
| Farxiga | Dapagliflozin Propanediol | 56 | 23 |
| Nyamyc | Nystatin | 56 | 11 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 55 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 55 | 16 |
| Buspirone Hcl | Buspirone Hcl | 48 | 11 |
| Calcitriol | Calcitriol | 48 | 19 |
| Montelukast Sodium | Montelukast Sodium | 47 | 16 |
| Mirtazapine | Mirtazapine | 45 | suppressed |
| Risperidone | Risperidone | 45 | suppressed |
| Allopurinol | Allopurinol | 44 | 16 |
| Divalproex Sodium | Divalproex Sodium | 44 | suppressed |
| Torsemide | Torsemide | 44 | 19 |
| Prednisone | Prednisone | 43 | 23 |
| Alprazolam | Alprazolam | 41 | 13 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 36 | 24 |
| Spironolactone | Spironolactone | 36 | 14 |
| Trazodone Hcl | Trazodone Hcl | 36 | 11 |
| Donepezil Hcl | Donepezil Hcl | 34 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 34 | 18 |
| Irbesartan | Irbesartan | 34 | 12 |
| Nystop | Nystatin | 34 | 13 |
| Jardiance | Empagliflozin | 33 | 12 |
| Valsartan | Valsartan | 33 | 14 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 31 | 12 |
| Olanzapine | Olanzapine | 29 | suppressed |
| Famotidine | Famotidine | 28 | 13 |
| Sucralfate | Sucralfate | 28 | suppressed |
| Bumetanide | Bumetanide | 26 | 12 |
| Escitalopram Oxalate | Escitalopram Oxalate | 24 | 12 |
| Memantine Hcl | Memantine Hcl | 24 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 23 | suppressed |
| Lokelma | Sodium Zirconium Cyclosilicate | 23 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 22 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 22 | 21 |
| Pravastatin Sodium | Pravastatin Sodium | 22 | 11 |
| Sertraline Hcl | Sertraline Hcl | 22 | suppressed |
| Cephalexin | Cephalexin | 21 | 19 |
| Finasteride | Finasteride | 21 | 11 |
| Glipizide Er | Glipizide | 21 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 21 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 21 | suppressed |
| Nifedipine Er | Nifedipine | 21 | suppressed |
| Latanoprost | Latanoprost | 20 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 20 | 20 |
| Trulicity | Dulaglutide | 20 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 19 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 19 | suppressed |
| Ezetimibe | Ezetimibe | 19 | 11 |
| Warfarin Sodium | Warfarin Sodium | 19 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 18 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 18 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 18 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 18 | 12 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Omeprazole | Omeprazole | 18 | 14 |
| Ozempic | Semaglutide | 18 | suppressed |
| Xarelto | Rivaroxaban | 18 | suppressed |
| Repaglinide | Repaglinide | 17 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 16 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 16 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 16 | suppressed |
| Hydroxyurea | Hydroxyurea | 16 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 16 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 16 | suppressed |
| Ranolazine Er | Ranolazine | 16 | suppressed |
| Azithromycin | Azithromycin | 15 | 14 |
| Fenofibrate | Fenofibrate Nanocrystallized | 15 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 15 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 14 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 14 | suppressed |
| Movantik | Naloxegol Oxalate | 14 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 13 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 13 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 13 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 13 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 13 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 13 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 13 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 13 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 13 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 13 | suppressed |
| Cinacalcet Hcl | Cinacalcet Hcl | 12 | suppressed |
| Digoxin | Digoxin | 12 | suppressed |
| Humalog | Insulin Lispro | 12 | suppressed |
| Januvia | Sitagliptin Phosphate | 12 | suppressed |
| Levetiracetam | Levetiracetam | 12 | suppressed |
| Meloxicam | Meloxicam | 12 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 11 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 11 | suppressed |
| Insulin Lispro | Insulin Lispro | 11 | suppressed |
| Kerendia | Finerenone | 11 | suppressed |
| Nystatin-Triamcinolone | Nystatin/Triamcinolone Acet | 11 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 11 | suppressed |
| Timolol Maleate | Timolol Maleate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $848.66 · 31 records | Novo Nordisk Inc | AREXVY, CLEVIPREX, Cologuard Collection Kit, FUROSCIX, JARDIANCE, JYNARQUE, KRYSTEXXA, Kerendia, Ozempic, Phasix Mesh, RAYALDEE, Rybelsus, SHINGRIX, TARPEYO, UPLIZNA, Wegovy | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Bayer Healthcare Pharmaceuticals Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error